Home » Stocks » Inozyme Pharma

Inozyme Pharma, Inc. (INZY)

Stock Price: $22.41 USD -0.08 (-0.36%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 500.08M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 20.31M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $22.41
Previous Close $22.49
Change ($) -0.08
Change (%) -0.36%
Day's Open 22.36
Day's Range 21.49 - 23.00
Day's Volume 98,017
52-Week Range 16.10 - 25.90

More Stats

Market Cap 500.08M
Enterprise Value 459.11M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 20.31M
Float 404,657
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.16
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 40.97M
Net Cash / Share 1.84
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-20.81-11.59
Net Income-19.72-6.96
Shares Outstanding1.181.05
Earnings Per Share-16.67-6.63
Operating Cash Flow-18.81-9.44
Capital Expenditures-0.14-0.26
Free Cash Flow-18.95-9.70
Cash & Equivalents47.2643.16
Net Cash / Debt47.2643.16
Book Value-33.22-13.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inozyme Pharma, Inc.
Country United States
Employees 24
CEO Axel Bolte

Stock Information

Ticker Symbol INZY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INZY
IPO Date July 24, 2020


Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.